Cellular b-2 microglobulin expression as a prognostic indicator in renal cell carcinoma

I. Levin, O. Kuperman, J. Goldstein, L. Neumann, S. Segal, J. Kaneti, L. Lismer, A. Machpud, B. Klein

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

The expression of B-2 microglobulin (B-2M) on tumor cells and their normal cell counterparts in 39 patients with renal cell carcinoma was studied and correlated to tumor stage and survival. The median survival time of patients with localized disease (stage I) whose tumors expressed B-2M was 10.2 years while the median survival time for patients whose tumors did not express B-2M was only 3.6 years (p < 0.001). For patients with more advanced disease (stages II, 111, IV) whose tumors expressed B-2M, median survival time was 3.6 years compared to 2.0 years in patients whose tumors did not express B-2M, a non-significant difference. It is suggested that the tumor cell membrane expression of B-2M may serve as an indicator of good prognosis in early renal cell carcinoma.

Original languageEnglish
Pages (from-to)941-945
Number of pages5
JournalActa Oncologica
Volume30
Issue number8
DOIs
StatePublished - 1 Jan 1991

Keywords

  • B-2 microglobulin
  • Renal cell carcinoma
  • Survival

Fingerprint

Dive into the research topics of 'Cellular b-2 microglobulin expression as a prognostic indicator in renal cell carcinoma'. Together they form a unique fingerprint.

Cite this